Catherine Arendt
About
Catherine Arendt is a scholar working on Immunology, Pathology and Forensic Medicine and Pediatrics, Perinatology and Child Health.
According to data from OpenAlex, Catherine Arendt has authored 21 papers receiving a total of 446 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 10 papers in Pathology and Forensic Medicine and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Catherine Arendt's work include Psoriasis: Treatment and Pathogenesis (12 papers), Autoimmune Bullous Skin Diseases (9 papers) and Pharmaceutical studies and practices (5 papers). Catherine Arendt is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (12 papers), Autoimmune Bullous Skin Diseases (9 papers) and Pharmaceutical studies and practices (5 papers). Catherine Arendt collaborates with scholars based in Belgium, United States and Germany. Catherine Arendt's co-authors include L Juhlin, Kristian Reich, Andrew Blauvelt, Alice B. Gottlieb, Luke Peterson, Daniel Burge, Janice Drew, M. Strolin Benedetti, Eugène Baltes and Craig L. Leonardi and has published in prestigious journals such as Annals of the Rheumatic Diseases, Journal of the American Academy of Dermatology and British Journal of Dermatology.
In The Last Decade
Catherine Arendt
18 papers receiving 430 citations
Peers
Catherine Arendt
Deepak M.W. Balak Netherlands
J. Crowley United States
Weiguo Xiao China
Ignasi Pau‐Charles Spain
Marek L. Kowalski Poland
N. Cichanowitz United States
Ella A.M. van der Voort Netherlands
S. von Schmiedeberg Germany
Jennifer Frueh Switzerland
L Botta Switzerland
Citations per year, relative to Catherine Arendt Catherine Arendt (= 1×)
peers
Deepak M.W. Balak
Countries citing papers authored by Catherine Arendt
Since
Specialization
Citations
This map shows the geographic impact of Catherine Arendt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Arendt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Arendt more than expected).
Fields of papers citing papers by Catherine Arendt
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Catherine Arendt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Arendt. The network helps show where Catherine Arendt may publish in the future.
Co-authorship network of co-authors of Catherine Arendt
This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Arendt. A scholar is included among the top collaborators of Catherine Arendt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Arendt. Catherine Arendt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Baust, Katja, Anja Borgmann‐Staudt, Gabriele Calaminus, et al.. (2025). Evaluation and implementation of multidisciplinary, standardized, guideline-based long-term follow-up care for adult survivors of childhood cancer in Germany: protocol of a prospective, multi-center, nationwide study (LE-Na). BMC Cancer. 25(1). 921–921.
2.
Blauvelt, Andrew, C. Paul, P.C.M. van de Kerkhof, et al.. (2020). Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies. British Journal of Dermatology. 184(4). 640–651.
3.
Lau, Chak Sing, et al.. (2020). Tuberculosis and viral hepatitis in patients treated with certolizumab pegol in Asia-Pacific countries and worldwide: real-world and clinical trial data. Clinical Rheumatology. 40(3). 867–875.
4.
Blauvelt, Andrew, C. Paul, Peter van de Kerkhof, et al.. (2020). Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies. SKIN The Journal of Cutaneous Medicine. 4(5). s46–s46.
5.
Blauvelt, Andrew, Bruce Strober, Richard G. Langley, et al.. (2019). Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96-Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT). SKIN The Journal of Cutaneous Medicine. 3. S39–S39.
6.
Gordon, Kenneth B., Richard B. Warren, A.B. Gottlieb, et al.. (2019). Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks in Patients with Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). SKIN The Journal of Cutaneous Medicine. 3. S36–S36.
7.
Gordon, Kenneth B., Richard B. Warren, A.B. Gottlieb, et al.. (2019). Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). SKIN The Journal of Cutaneous Medicine. 3. S37–S37.
8.
Kang, Young Mo, Young Eun Park, Won Park, et al.. (2018). Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis. The Korean Journal of Internal Medicine. 33(6). 1224–1233.
9.
Gottlieb, Alice B., Andrew Blauvelt, Diamant Thaçi, et al.. (2018). Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). Journal of the American Academy of Dermatology. 79(2). 302–314.e6.
10.
Blauvelt, Andrew, Kristian Reich, Mark Lebwohl, et al.. (2018). Certolizumab Pegol for the Treatment of Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Overview of 3 Randomized Controlled Trials. SKIN The Journal of Cutaneous Medicine. 2. S3–S3.
11.
Blauvelt, Andrew, Kristian Reich, Mark Lebwohl, et al.. (2018). Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. Journal of the European Academy of Dermatology and Venereology. 33(3). 546–552.
12.
Augustin, Matthias, Mark Lebwohl, C. Paul, et al.. (2018). Clinical Response in Plaque Psoriasis Patients Switching from Etanercept to Certolizumab Pegol in a Phase 3, Randomized, Controlled Study. SKIN The Journal of Cutaneous Medicine. 2. S86–S86.
13.
Thaçi, Diamant, Alice B. Gottlieb, Kristian Reich, et al.. (2017). Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2). SKIN The Journal of Cutaneous Medicine. 1. s4–s4.
14.
Reich, Kristian, Andrew Blauvelt, Diamant Thaçi, et al.. (2017). Maintenance of Response with Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: 48-Week Results from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2). SKIN The Journal of Cutaneous Medicine. 1. s23–s23.
15.
Emery, Paul, Clifton O. Bingham, Gerd R Burmester, et al.. (2016). Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Annals of the Rheumatic Diseases. 76(1). 96–104.
16.
Loftus, Edward V., Jean‐Frédéric Colombel, Stefan Schreiber, et al.. (2016). Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials. Clinical Gastroenterology and Hepatology. 14(12). 1753–1762.
17.
Smolen, Josef S, Ronald van Vollenhoven, Arthur Kavanaugh, et al.. (2015). Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Arthritis Research & Therapy. 17(1). 245–245.
18.
Arendt, Catherine, et al.. (2014). P-105 Dermatologic Complications in Patients Treated with Certolizumab Pegol. Inflammatory Bowel Diseases. 20. S70–S71.
19.
Benedetti, M. Strolin, et al.. (2001). Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. European Journal of Clinical Pharmacology. 57(8). 571–582.
20.
Juhlin, L & Catherine Arendt. (1988). Treatment of chronic urticaria with cetirizine dihydrochloride a non-sedating antihistamine. British Journal of Dermatology. 119(1). 67–72.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Deepak M.W. Balak Breakdown of academic impact, for papers by J. Crowley Breakdown of academic impact, for papers by Weiguo Xiao Breakdown of academic impact, for papers by Ignasi Pau‐Charles Breakdown of academic impact, for papers by Marek L. Kowalski Breakdown of academic impact, for papers by N. Cichanowitz Breakdown of academic impact, for papers by Ella A.M. van der Voort Breakdown of academic impact, for papers by S. von Schmiedeberg Breakdown of academic impact, for papers by Jennifer Frueh Breakdown of academic impact, for papers by L Botta